Eclosion SA
Eclosion SA (Eclosion Ventures) is a Geneva-based, privately held life science venture capital firm founded in 2001 that manages the Eclosion2 fund, investing in and building early-stage biotechnology companies developing first-in-class therapeutics in multiple sclerosis, fibrosis, and oncology from seed through clinical proof of concept.
- Company typePrivate
- Founded2001
- HeadquartersGeneva, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
Eclosion SA firmographics
Firmographics- Name
- Eclosion SA
- Legal name
- Eclosion SA
- Website
- https://eclosion.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Eclosion SA (Eclosion Ventures) is a Geneva-based, privately held life science venture capital firm founded in 2001 that manages the Eclosion2 fund, investing in and building early-stage biotechnology companies developing first-in-class therapeutics in multiple sclerosis, fibrosis, and oncology from seed through clinical proof of concept.
- Ownership category
- akta.pro rank
Eclosion SA industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment
- NAICS
- All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Accelerators & Incubators (Investor-Operated) (FSANAAAM)
Keywords
Where Eclosion SA is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Eclosion SA business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Revenue model
- Investment Fund Management: Eclosion Ventures manages the Eclosion life science investment fund, generating returns through equity investments in early-stage biotechnology companies. Revenue is derived from portfolio company value appreciation, exits via acquisitions or IPOs, and management fees or carried interest from the fund structure.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Eclosion SA product offering
Product offeringCore offering
Eclosion SA (operating as Eclosion Ventures) manages the Eclosion life science investment fund (Eclosion2), which invests in highly innovative early-stage biotechnology companies developing first-in-class drugs and platform technologies. The fund provides significant long-term operational and financial commitments from seed stage through capital stage up to clinical proof of concept, targeting therapeutics in fields such as multiple sclerosis, fibrosis, and oncology.
Product overview
Eclosion Ventures manages a single unified investment fund focused on the life sciences and biotechnology sector. The Eclosion Life Science Investment Fund serves as the core offering, providing significant long-term operational and financial commitments to early-stage companies developing first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis, and oncology. The fund operates from seed stage through clinical proof of concept, functioning as both builder and enabler for portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Eclosion Life Science Investment Fund (Eclosion2) A private investment fund that deploys capital and operational support into early-stage biotechnology companies developing first-in-class drugs and platform technologies with high unmet medical need. Targets translational science from seed through clinical proof of concept in therapeutics areas including multiple sclerosis, fibrosis, and oncology. For biotech founders and entrepreneurs seeking capital and operational backing.
Companies that use Eclosion SA
Customer profileSegments1 record
Ideal customer profiles1 record
Eclosion SA technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Eclosion SA partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights2 records
Eclosion SA competitors and assessment
Company assessmentDirect peers
- Ysios Capital: Spanish-based venture capital firm specializing in life sciences and biotech investments across development stages; comparable as a European biotech-focused investor.
- TVM Capital Life Science: Transatlantic life-sciences VC with European roots investing across early- and late-stage biotech and medtech; comparable as a sector-specialist European life-sciences investor.
- LSP (Life Sciences Partners): European life-sciences investment firm investing in public and private biotech and medical-technology companies; comparable as a long-standing European life-sciences specialist.
- Forbion: European life-sciences VC firm managing multiple funds investing across development stages in biotech and therapeutic platforms; comparable as a sector-focused European life-sciences investor.
- Medicxi: European venture capital firm focused on early-stage life sciences and biotech investing with a company-creation ethos; comparable to Eclosion in stage focus and therapeutic orientation.
- BioGeneration Ventures: Dutch-based European early-stage biotech VC that creates and backs life-sciences companies from seed onward; closely mirrors Eclosion's early-stage, builder-style approach in Europe.
- Apollo Therapeutics: UK-based biotech venture firm investing in translational therapeutics from major academic institutions; comparable as an early-stage, science-driven European biotech investor.
- Sofinnova Partners: One of Europe's largest life-sciences VC firms investing across biotech from early stage through clinical development; directly comparable as a European life-sciences fund manager.
- Kurma Partners: European healthcare and life-sciences investor active from seed through growth stage with an entrepreneurial approach; comparable to Eclosion in stage mix and therapeutic focus.
Broad incumbents
- Index Ventures (Life Sciences): Broad European VC firm with a dedicated life-sciences practice investing in biotech from early stage; comparable as a European life-sciences investor but operating as part of a larger multi-stage generalist platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Eclosion SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eclosion SA leadership team
Management profileNumber of profiles
Profiles1 record
Eclosion SA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eclosion SA M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eclosion SA
What does Eclosion SA do?
Eclosion SA (operating as Eclosion Ventures) manages the Eclosion life science investment fund (Eclosion2), which invests in highly innovative early-stage biotechnology companies developing first-in-class drugs and platform technologies. The fund provides significant long-term operational and financial commitments from seed stage through capital stage up to clinical proof of concept, targeting therapeutics in fields such as multiple sclerosis, fibrosis, and oncology.
Is Eclosion SA a public or private company?
Eclosion SA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Eclosion SA founded?
Eclosion SA was founded in 2001. It employs 1 to 10 people.
Where is Eclosion SA based?
Eclosion SA is headquartered in Geneva, Switzerland, in the Europe region.
How does Eclosion SA make money?
One revenue line is on record: investment Fund Management.
Who are Eclosion SA's main competitors?
Direct peers on record are Ysios Capital, TVM Capital Life Science, LSP (Life Sciences Partners), Forbion, Medicxi, BioGeneration Ventures, Apollo Therapeutics, Sofinnova Partners and Kurma Partners. Index Ventures (Life Sciences) is listed as a broad incumbent.
Does Eclosion SA have an API?
No public API is recorded for Eclosion SA.
What industry is Eclosion SA in?
Eclosion SA's product category is Venture Capital / Life Sciences Investment. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated). Its NAICS code is 52399 and its SIC code is 6282.